- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02796196
Prescribed Physical Activity in Improving Sleep and Physical Performance in Patients Undergoing Stem Cell Transplant
Effects of Prescribed Physical Activity on Sleep and Performance in Hematopoietic Cell Transplantation Patients
연구 개요
상세 설명
PRIMARY OBJECTIVES:
I. Evaluate whether prescribed physical activity, as part of standard care, improves sleep and functional outcomes in hematopoietic cell transplantation (HCT) (stem cell transplantation) patients during a typical 30-day hospitalization period.
OUTLINE:
Data including demographics, type of HCT (e.g., allogeneic or autologous), preexisting physical conditions (e.g., chronic joint injury), chronic renal failure (CRF), steroid use data, Eastern Cooperative Oncology Group (ECOG) and Karnofsky performance status (KPS) scores are collected from patients' medical charts at time of enrollment. Patients are prescribed participation in a primarily self-directed physical activity program which encourages them to spend 6 hours out of bed daily and to perform 30 minutes of light-to-moderate daily aerobic activity. Patients who are able to maintain independent mobility undergo physical therapist assessment 2 times a week until hospital discharge. Patients wear a physical activity monitoring device and daily activity and sleep data are collected continuously during hospital length of stay (LOS).
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
California
-
Palo Alto, California, 미국, 94304
- Stanford University, School of Medicine
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 어린이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Admitted to Stanford Hospital for HCT
- Able to provide informed consent
- Speaks language supported by interpretative services
- Able to operate and take care of a physical activity monitor
Exclusion Criteria:
- Does not meet inclusion criteria
- Unable to wear a physical activity monitor throughout hospital stay
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Supportive care (monitoring device, medical chart review)
Data including demographics, type of HCT (e.g., allogeneic or autologous), preexisting physical conditions (e.g., chronic joint injury), CRF, steroid use data, ECOG and KPS scores are collected from patients' medical charts at time of enrollment.
Patients are prescribed participation in a primarily self-directed physical activity program which encourages them to spend 6 hours out of bed daily and to perform 30 minutes of light-to-moderate daily aerobic activity.
Patients who are able to maintain independent mobility undergo physical therapist assessment 2 times a week until hospital discharge.
Patients wear a physical activity monitoring device and daily activity and sleep data are collected continuously during hospital LOS.
|
의료 차트 검토
다른 이름들:
Wearable physical activity monitoring device
다른 이름들:
Undergo primarily self-directed physical therapy
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
ECOG performance scores
기간: At baseline
|
Will focus on trends in scores between patients with different durations of activity and sleep.
Results, from both descriptive and inferential analyses, will be presented in table and/or graphical format.
|
At baseline
|
|
KPS performance scores
기간: At baseline
|
Will focus on trends in scores between patients with different durations of activity and sleep.
Results, from both descriptive and inferential analyses, will be presented in table and/or graphical format.
|
At baseline
|
|
Minutes of aerobic activity per day
기간: Up to time of hospital discharge, or 29 days
|
Will use interval-censored regression to estimate distributions of activity from one day to the next.
This repeated-measures analysis with a polynomial model will generate average curves for activity, each spanning average LOS (i.e., activity duration plotted on day one, day two, day three, etc.).
Will also run diagnostics to verify the assumptions of a linear model (e.g., statistical independence of observations and lack of undue influence of outliers on model fit).
|
Up to time of hospital discharge, or 29 days
|
|
Minutes of sleep per day
기간: Up to time of hospital discharge, or 29 days
|
Will use interval-censored regression to estimate distributions of sleep from one day to the next.
This repeated-measures analysis with a polynomial model will generate average curves for sleep, each spanning average LOS (i.e., sleep duration plotted on day one, day two, day three, etc.).
Will use multiple linear regressions to control for potential confounders in predicting sleep duration.
Will also run diagnostics to verify the assumptions of a linear model (e.g., statistical independence of observations and lack of undue influence of outliers on model fit).
|
Up to time of hospital discharge, or 29 days
|
공동 작업자 및 조사자
수사관
- 수석 연구원: André Valdez, Stanford University
- 수석 연구원: Matthew Smuck, Stanford University
- 수석 연구원: Kota Reichert, Stanford University
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- IRB-35379 (기타 식별자: Stanford IRB)
- NCI-2016-00737 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
- VAR0137 (기타 식별자: Stanford Cancer Institute)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
세포 이식에 대한 임상 시험
-
Sandy SrinivasGlaxoSmithKline완전한방광암 | 방광(요로상피, 이행세포) 암 | 방광(Urothelial, Transitional Cell) 절제 가능한 암(방광절제술 전) | 방광(Urothelial, Transitional Cell) 암 표재성(비침습성) | 방광(Urothelial, Transitional Cell) 암 전이성 또는 절제 불가능미국
-
Ain Shams University완전한방광(Urothelial, Transitional Cell) 암 표재성(비침습성) | Transurethral Resection of Bladder Tumor이집트
-
Fondazione Policlinico Universitario Agostino Gemelli...모병상부 요로상피암 | 방광(Urothelial, Transitional Cell) 암 전이성 또는 절제 불가능이탈리아
-
Ankara UniversityFondazione IRCCS Istituto Nazionale dei Tumori, Milano아직 모집하지 않음방광(Urothelial, Transitional Cell) 암 전이성 또는 절제 불가능
-
Stanford UniversityNational Institutes of Health (NIH)빼는방광암 | 피부암 | 방광(요로상피, 이행세포) 암 | 방광(Urothelial, Transitional Cell) 절제 가능한 암(방광절제술 전)미국
-
Relmada Therapeutics, Inc.빼는요로상피암 방광 | 비뇨기과 암 | 요로상피암 재발성 | 방광(요로상피, 이행세포) 암 | 방광(Urothelial, Transitional Cell) 암 표재성(비침습성)
-
Ciusss de L'Est de l'Île de MontréalStem Cell Network모병급성 백혈병, 고위험군 | 고위험 골수형성이상증후군 | Hematologic Malignancy Requiring an Allogeneic Hematopoietic Stem Cell Transplant Lacking a Donor캐나다
-
Relmada Therapeutics, Inc.빼는요로상피암 방광 | 비뇨기과 암 | 방광(요로상피, 이행세포) 암 | 방광(Urothelial, Transitional Cell) 암 표재성(비침습성)
-
Millennium Pharmaceuticals, Inc.완전한GCB(Non-Germinal B-cell-like) 미만성 거대 B-세포 림프종(DLBCL)미국
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI); Genentech, Inc.모병미만성 거대 B세포 림프종 | 재발성 미만성 대형 B세포 림프종 | 난치성 미만성 대형 B세포 림프종 | 원발성 종격동(흉선) 대형 B세포 림프종 | 등급 3b 여포성 림프종 | 변형된 여포 림프를 Diff 대형 B-세포 림프종으로 | 변형된 마그 존 림프를 Diff Large B-Cell Lymphoma로미국
의료 차트 검토에 대한 임상 시험
-
Schön Klinik Berchtesgadener Land완전한
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University모병